Literature DB >> 19549602

Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.

Sung-Wuk Jang1, Xia Liu, Chi-Bun Chan, David Weinshenker, Randy A Hall, Ge Xiao, Keqiang Ye.   

Abstract

Neurotrophins, the cognate ligands for the Trk receptors, are homodimers and induce Trk dimerization through a symmetric bivalent mechanism. We report here that amitriptyline, an antidepressant drug, directly binds TrkA and TrkB and triggers their dimerization and activation. Amitriptyline, but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes TrkA autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells. Amitriptyline binds the extracellular domain of both TrkA and TrkB and promotes TrkA-TrkB receptor heterodimerization. Truncation of amitriptyline binding motif on TrkA abrogates the receptor dimerization by amitriptyline. Administration of amitriptyline to mice activates both receptors and significantly reduces kainic acid-triggered neuronal cell death. Inhibition of TrkA, but not TrkB, abolishes amitriptyline's neuroprotective effect without impairing its antidepressant activity. Thus, amitriptyline acts as a TrkA and TrkB agonist and possesses marked neurotrophic activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549602      PMCID: PMC2844702          DOI: 10.1016/j.chembiol.2009.05.010

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  42 in total

1.  TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor.

Authors:  J C Arevalo; B Conde; B L Hempstead; M V Chao; D Martin-Zanca; P Perez
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

2.  Design and solution structure of functional peptide mimetics of nerve growth factor.

Authors:  N Beglova; S Maliartchouk; I Ekiel; M C Zaccaro; H U Saragovi; K Gehring
Journal:  J Med Chem       Date:  2000-09-21       Impact factor: 7.446

Review 3.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

Review 4.  The treatment of neuropathic pain: antidepressants and opioids.

Authors:  C P Watson
Journal:  Clin J Pain       Date:  2000-06       Impact factor: 3.442

5.  Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects.

Authors:  Y Xie; M A Tisi; T T Yeo; F M Longo
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

6.  p75-mediated neuroprotection by NGF against glutamate cytotoxicity in cortical cultures.

Authors:  T Kume; H Nishikawa; H Tomioka; H Katsuki; A Akaike; S Kaneko; T Maeda; T Kihara; S Shimohama
Journal:  Brain Res       Date:  2000-01-10       Impact factor: 3.252

7.  Mapping the differences in the brain concentration of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in an animal model of depression.

Authors:  F Angelucci; L Aloe; P J Vasquez; A A Mathé
Journal:  Neuroreport       Date:  2000-04-27       Impact factor: 1.837

8.  Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurotrophin receptor P75.

Authors:  C Culmsee; N Gerling; M Lehmann; M Nikolova-Karakashian; J H M Prehn; M P Mattson; J Krieglstein
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

9.  Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats.

Authors:  R Hellweg; U E Lang; M Nagel; A Baumgartner
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 10.  Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?

Authors:  Stuart C Apfel
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

View more
  48 in total

1.  Tricyclic antidepressant amitriptyline activates fibroblast growth factor receptor signaling in glial cells: involvement in glial cell line-derived neurotrophic factor production.

Authors:  Kazue Hisaoka; Mami Tsuchioka; Ryoya Yano; Natsuko Maeda; Naoto Kajitani; Norimitsu Morioka; Yoshihiro Nakata; Minoru Takebayashi
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 2.  Metabolic reserve as a determinant of cognitive aging.

Authors:  Alexis M Stranahan; Mark P Mattson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Advances in intravesical therapy for urinary tract disorders.

Authors:  Pradeep Tyagi; Mahendra Kashyap; Harvey Hensley; Naoki Yoshimura
Journal:  Expert Opin Drug Deliv       Date:  2015-10-19       Impact factor: 6.648

4.  The CB₁ receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin.

Authors:  Parichehr Hassanzadeh; Anna Hassanzadeh
Journal:  Neurochem Res       Date:  2012-02-07       Impact factor: 3.996

5.  Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.

Authors:  Timothy J Collier; Kinshuk R Srivastava; Craig Justman; Tom Grammatopoulous; Birgit Hutter-Paier; Manuela Prokesch; Daniel Havas; Jean-Christophe Rochet; Fang Liu; Kevin Jock; Patrícia de Oliveira; Georgia L Stirtz; Ulf Dettmer; Caryl E Sortwell; Mel B Feany; Peter Lansbury; Lisa Lapidus; Katrina L Paumier
Journal:  Neurobiol Dis       Date:  2017-07-12       Impact factor: 5.996

Review 6.  New treatments for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Adam C Strauss; Jordan D Dimitrakov
Journal:  Nat Rev Urol       Date:  2010-02-09       Impact factor: 14.432

7.  Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus.

Authors:  Henri Autio; Kert Mätlik; Tomi Rantamäki; Lothar Lindemann; Marius C Hoener; Moses Chao; Urmas Arumäe; Eero Castrén
Journal:  Neuropharmacology       Date:  2011-07-30       Impact factor: 5.250

8.  Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism.

Authors:  Katrina L Paumier; Caryl E Sortwell; Lalitha Madhavan; Brian Terpstra; Stephanie L Celano; Joshua J Green; Nastassja M Imus; Nathan Marckini; Brian Daley; Kathy Steece-Collier; Timothy J Collier
Journal:  Neuropsychopharmacology       Date:  2014-09-30       Impact factor: 7.853

9.  The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension.

Authors:  Zoya Marinova; Susanne Walitza; Edna Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2017-03-18       Impact factor: 3.575

Review 10.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.